The California Health Care Foundation (CHCF) has awarded The Institute for Clinical and Economic Review (ICER) a new grant to develop 2 California-specific unsupported price increase reports. In addition, the grant will support the development of a policymaker guide to use comparative effectiveness research to ensure fair drug prices. This is on top of continued financial support for ICER value assessments reviewed by the California Technology Assessment Forum (CTAF).
According to Sarah K. Emond, MPP, ICER's Executive Vice President and Chief Operating Officer, “For nine years, funding from CHCF has allowed ICER to lead a national discussion about how to align the prices in our health care system with the benefits patients receive from various treatments, therapies, and interventions. Policymakers are now regularly referencing ICER's health-benefit price benchmarks when crafting legislation to address rising US health care costs, especially around prescription drug spending.”
Click here to read more.
(Source: ICER, March 3rd, 2022)